Evidence map›Paper›PMID 39039410›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

Expression and Purification of RVFV Glycoprotein C for Structural Studies Using Baculovirus Expression System.

Suryakant Tiwari, Moshe Dessau

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Suryakant TiwariAzrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Moshe DessauAzrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel. moshe.dessau@biu.ac.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Rift Valley fever virus (RVFV), transmitted through mosquito bites, leads to severe illness in humans and livestock throughout Africa and the Arabian Peninsula, causing significant morbidity and mortality. As of now, there are no verified and efficacious drugs or licensed vaccines accessible for the prevention or treatment of RVFV infections in both humans and livestock. The mature RVFV virion has two envelope proteins on its surface: glycoprotein N (G

Indexed as

BaculoviridaeRecombinant ProteinsRift Valley fever virusViral Envelope ProteinsAnimalsCloning, MolecularGene ExpressionGenetic VectorsHumansSf9 CellsRecombinant ProteinsViral Envelope ProteinsAffinity chromatographyBaculovirus expression in insect cellsClass II membrane fusion proteinsPhenuiviridaeRVFV GCSecreted protein

Identifiers

PMID39039410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.